Skip Navigation


JAC Advance Access originally published online on August 7, 2009
Journal of Antimicrobial Chemotherapy 2009 64(4):810-814; doi:10.1093/jac/dkp281
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
64/4/810    most recent
dkp281v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Alhanout, K.
Right arrow Articles by Rolain, J.-M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alhanout, K.
Right arrow Articles by Rolain, J.-M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis

Kamel Alhanout, Jean-Michel Brunel, Didier Raoult and Jean-Marc Rolain*

URMITE UMR 6236, CNRS-IRD, Faculté de Médecine et de Pharmacie, 27 Boulevard Jean Moulin, 13385 Marseille cedex 05, France

Received 13 March 2009; returned 27 April 2009; revised 29 May 2009; accepted 12 July 2009


* Corresponding author: Tel: +33-4-91-32-43-75; Fax: +33-4-91-38-77-72; E-mail: jean-marc.rolain{at}univmed.fr

Objectives: Respiratory infections with multidrug-resistant (MDR) bacteria are life-threatening in patients with cystic fibrosis (CF). Squalamine and aminosterol derivatives (ASDs) have previously demonstrated interesting antibacterial activity against bacterial reference strains. This study investigated for the first time their activity against MDR clinical isolates recovered from the sputa of CF patients.

Methods: Antibacterial activity of squalamine and two ASDs (1 and 2) was evaluated against 135 MDR Gram-negative and Gram-positive bacteria using the broth microdilution method for MIC determination.

Results: For Gram-negative bacteria, MICs ranged from 2 to 128 mg/L. Resistance to colistin and mucoidity were significantly associated with higher MICs of squalamine and ASDs 1 and 2. Tested compounds were active against various Gram-positive bacteria with MIC values varying from 0.5 to 8 mg/L, with the exception of two capsulated isolates of Streptococcus pneumoniae demonstrating MICs of 32 mg/L.

Conclusions: In this study, we present new findings concerning the antibacterial potential of ASDs against MDR bacteria. Colistin-resistant, mucoid and capsulated bacteria were found to exhibit decreased susceptibility to ASDs indicating that these compounds might share some mechanistic aspects with polymyxins towards Gram-negative bacteria. However, ASDs were remarkably active against Gram-positive species suggesting different mechanisms of action towards Gram-positive and Gram-negative bacteria. As tested ASDs exhibited elevated MICs in some cases, we believe that these compounds may be developed to be locally administrated as aerosols rather than via systemic administration routes. Further work is warranted to evaluate their in vivo efficacy in aerosol formulations using a lung-infected animal model.

Keywords: squalamine , antibiotics , infections


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.